Longitudinal Radiological Findings in Patients With COVID-19 With Different Severities: From Onset to Long-Term Follow-Up After Discharge

Yajing Zhao 1†, Dongdong Wang 1†, Nan Mei 1†, Bo Yin 1, Xuanxuan Li 1, Yingyan Zheng 1, Anling Xiao 2, Xiangrong Yu 3, Xiaohui Qiu 4, Yiping Lu* and Li Liu 5*

1 Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China, 2 Department of Radiology, Fuyang Second People’s Hospital, Fuyang, China, 3 Department of Radiology, Zhuhai People’s Hospital, Zhuhai, China, 4 Department of Radiology, Bozhou People’s Hospital, Bozhou, China, 5 Department of Radiology, Shanghai Cancer Center, Fudan University, Shanghai, China

Objective: This study aimed to investigate the evolution of radiologic findings in the patients with coronavirus disease 2019 (COVID-19) pneumonia with different severities from onset to 1-year follow-up and identify the predictive factors for different pulmonary lesion absorption status in the patients infected with COVID-19.

Methods: A retrospective study was performed on the clinical and radiological features of 175 patients with COVID-19 pneumonia hospitalized at three institutions from January 21 to March 20, 2020. All the chest CT scans during hospitalization and follow-ups after discharge were collected. The clinical and radiological features from the chest CT scans both at the peak stage and before discharge from the hospital were used to predict whether the pulmonary lesions would be fully absorbed after discharge by Cox regression. Then, these patients were stratified into two groups with different risks of pulmonary lesion absorption, and an optimal timepoint for the first CT follow-up was selected accordingly.

Results: A total of 132 (75.4%) patients were classified into the non-severe group, and 43 (24.6%) patients were classified into the severe group, according to the WHO guidelines. The opacification in both the groups changed from ground-glass opacity (GGO) to consolidation and then from consolidation to GGO. Among the 175 participants, 135 (112 non-severe and 23 severe patients with COVID-19) underwent follow-up CT scans after discharge. Pulmonary residuals could be observed in nearly half of the patients (67/135) with the presentation of opacities and parenchymal bands. The parenchymal bands in nine discharged patients got fully absorbed during the follow-up periods. The age of patient [hazard ratio (HR) = 0.95, 95% CI, 0.95–0.99], level of lactate dehydrogenase (LDH) (HR = 0.99; 95% CI, 0.99–1.00), level of procalcitonin (HR = 8.72; 95% CI, 1.04–73.03), existence of diffuse lesions (HR = 0.28; 95% CI, 0.09–0.92), subpleural distribution of lesions (HR = 2.15; 95% CI, 1.17–3.92), morphology of residuals (linear lesion: HR = 4.58, 95% CI, 1.22–17.11; nodular lesion: HR = 33.07, 95% CI, 3.58–305.74), and pleural traction (HR = 0.41; 95% CI, 0.22–0.78) from the...
last scan before discharge were independent factors to predict the absorption status of COVID-19-related pulmonary abnormalities after discharge. According to a Kaplan–Meier analysis, the probability of patients of the low-risk group to have pulmonary lesions fully absorbed within 90 days reached 91.7%.

**Conclusion:** The development of COVID-19 lesions followed the trend from GGO to consolidation and then from consolidation to GGO. The CT manifestations and clinical and laboratory variables before discharge could help predict the absorption status of pulmonary lesions after discharge. The parenchymal bands could be fully absorbed in some COVID-19 cases. In this study, a Cox regression analysis indicated that a timepoint of 3 months since onset was optimal for the radiological follow-up of discharged patients.

**Keywords:** COVID-19, longitudinal, follow-up, prognosis, parenchymal bands

## INTRODUCTION

The contemporary emerging coronavirus disease 2019 (COVID-19) has become an international public health event, and the death toll reached over 3 million as of April 20, 2021 (1, 2). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is identified as the pathogen of COVID-19, which shares a structural similarity with severe acute respiratory syndrome coronavirus (SARS-CoV), binding with angiotensin-converting enzyme 2 (ACE2) receptors via the spike protein (S-protein) to invade host cells (3, 4). Although multiple organs were reported to be affected by SARS-CoV-2, given the high expression of ACE2 receptor in type II lung cells, the respiratory system was still the first and main organ to be damaged (5, 6).

Currently, chest CT is the main imaging facility to detect and manage COVID-19 related pneumonia (7, 8). Based on high accuracy in COVID-19 diagnosis, chest CT imaging was once placed in an unusually important position, bearing the potential to replace nucleic acid amplification test (NAAT) at the beginning of the outbreak. With the improvement of the accuracy and speed of the NAAT, chest CT imaging is no longer a determinant diagnostic tool for COVID-19 but remains an important tool for disease evaluation. Multiple studies have described the short-term CT manifestations in the patients infected with COVID-19, while few studies have investigated their long-term CT findings after discharge (9–11). According to the updated guidelines of the Government of China, patients with COVID-19 were required to undergo follow-ups at 2 and 4 weeks after discharge with or without imaging surveillance (12). In the guidelines published by the British Thoracic Society, imaging follow-up is recommended for all the patients with COVID-19 admitted to the hospital 3 months after discharge based on the experience of SARS and Middle East respiratory syndrome (MERS) (6, 13, 14). Without enough follow-up studies, the optimal time for follow-up imaging to assess radiological clearance in COVID-19 is unclear. Therefore, it is important to clarify the dynamic changes in COVID-19 related pulmonary abnormalities from onset to the convalescence stage that could help us understand the disease comprehensively and make customized follow-up plans for different individuals.

It has been over 1 year since the outbreak of COVID-19 in China. Most patients with COVID-19 were discharged and had already undergone several follow-up CT scans. In this study, we collected all CT scans from the survivors of COVID-19 in multiple institutions to investigate the longitudinal radiological development in patients with different clinical types during hospitalization and follow-ups, aiming to depict the longitudinal changes in pulmonary lesions, select the important features to impact the resolution of chest CT abnormalities in patients with COVID-19, and provide evidence to make optimal imaging surveillance plans for different patients.

## MATERIALS AND METHODS

### Patient Cohort

The institutional review board approved this multicenter retrospective study and waived the requirement of written informed consent. Deidentified data were used to prevent any leak of the patient's privacy. The patients admitted to the three hospitals in Anhui and Hubei Provinces in China from January 21 to March 20, 2020 and who met the following requirements were enrolled in our study: (1) patients with laboratory-confirmed COVID-19 infection by NAAT; (2) patients who had pneumonia manifestations on at least one chest CT scan during hospitalization; (3) at least two chest CT scans during hospitalization (at admission and before discharge) were required; and (4) no significant artifacts were presented in the CT images. The exclusion criteria were as follows: (a) patients who were transferred from other hospitals (n = 5); (b) patients whose chest CT findings were negative (n = 11); (c) lack of chest CT scans at the time of admission (n = 28); and (d) the unqualified CT scans or images (n = 2).

The epidemiological history, main complaints, underlying comorbidity, chest CT imaging features, and laboratory test results at the time of admission were recorded. The clinical types were initially determined based on the guidelines proposed by China and WHO, such as mild, moderate, severe, and critical types (12, 15). The criteria are provided in **Supplementary Table 1**. The mild and moderate cases were categorized into the non-severe group, while severe and critical types were classified into the severe group. All the enrolled
patients with COVID-19 underwent CT scans at admission and before discharge. According to the guidelines version 5.0–7.0 issued by the Government of China, the treatment used during hospitalization was also recorded. Referring to the guidelines version 7 of China, all the patients were recommended to undergo at least one follow-up CT scan within 1 month after discharge (16). If abnormalities were detected, the patient was recommended to undergo a follow-up CT 3 months later. The workflow of the study is shown in Figure 1.

Clinical Course Assessment
The onset date was recorded as the day when symptoms first appeared. The onset date, admission date, date of transfer to the intensive care unit (ICU), date of transfer out of the ICU, two NAAT test dates, discharge date, and each CT scan date, were recorded. The duration of admission was calculated from the 1st day of hospitalization to the day of discharge. The clinical course was calculated from the day of onset to the day of discharge. The absorption period was calculated from the day of onset to the day of a CT scan with normal appearance.

CT Protocol
A total of 175 patients were enrolled from three institutions in Anhui and Hubei Provinces, China. Unenhanced CT scans were applied to all the patients. Patients were imaged with a 64-section CT scanner (Aquilion 64, Toshiba Medical Systems, Otawara, Japan/Somatom Sensation, Siemens, Germany) or a 16-section CT scanner (Emotion 16, Siemens Medical Solutions, Erlangen, Germany). The parameters used for the scanning protocol were as followed: patient in the supine position; end inspiratory acquisition; tube voltage, 100–120 kV; tube current–exposure time product, 200–300 mAs; pitch, 1.375 and 0.9125; and section thickness after reconstruction, 1.25 mm. The images were displayed at lung (window width, 1,500 HU; window level, −500 HU) and mediastinal (window width, 320 HU; window level, 40 HU) windows.

CT Manifestation Analysis
All the imaging data were analyzed with consensus by two experienced radiologists (10 and 8 years of clinical experience) who were blinded to the clinical data and consensus was reached after negotiation.

For all the CT scans, 15 pulmonary lesion related parameters were collected as listed below: (a) the involved pulmonary lobes; (b) the location of pulmonary lesions, such as subpleural, central, or both; (c) the extent of the lesions, such as unifocal, multifocal, and diffuse; (d) a semi-quantitative scoring system (Extent Score) was used to estimate the extent (17, 18). Each lung was divided into upper (above the tracheal carina), lower (below the inferior pulmonary vein), and middle (in between) zones, and each zone was scored based on the following criteria: 0, 0%; 1, < 25%; 2, 25–49%; 3, 50–74%; and 4, > 75%. The extent of abnormalities was determined by the summation of scores (possible range 0–24); (e) the existence of opacification, such as ground-glass opacity (GGO), mixed (mainly GGO, mainly consolidation), and consolidation; (f) the morphology of the lesions, such as nodular (characterized on CT scans as a rounded or irregular opacity, well or poorly defined, measuring up to 3 cm in diameter), linear (fine linear opacity), patchy (isolated focal lesions with no nodular/linear shape in the segment), and large patchy (large fused lesions involving multiple segments); the existence of a/an (g) “crazy-paving” pattern; (h) halo sign; (i) reversed halo sign (RHS); (j) reticular pattern; (k) vascular enlargement; (l) air bronchogram; (m) bronchioloclastia; (n) pleural thickening; (o) pleural traction; (p) of pleural effusion; and (q) mediastinal lymphadenopathy (the minimal axial diameter >1 cm) (19). The descriptions of radiological features used the definitions compiled by the Fleischner Society (20).

For follow-up scans, except for the assessments above, each CT scan was labeled normal or abnormal according to the existence of pulmonary lesions for further analysis.

Statistical Analysis
All the statistical analyses were performed with R software (version 3.5.3; R Foundation for Statistical Computing, Vienna, Austria). The Shapiro–Wilk test was used to evaluate the distribution type, and Bartlett’s test was used to evaluate the homogeneity of variance. Normally distributed data are expressed as the mean ± SD. Non-normally distributed data and ordinal data are expressed as medians [interquartile ranges (IQRs)]. The categorical variables were summarized as counts and percentages. Comparisons of non-paired quantitative data were evaluated using the Mann–Whitney U-test and Wilcoxon’s test. Comparisons of categorized data were evaluated by the chi-square test and Fisher’s test. A value of $p < 0.05$ was defined as statistically significant.

To identify the important variables to stratify patients with/without pulmonary residual lesions, all the clinical and laboratory variables and CT manifestations before discharge and at the peak stage were evaluated by univariate Cox proportional hazards regression analyses and factors with a value of $p < 0.05$ were further assessed in the multivariate Cox proportional hazards regression analysis.

RESULTS
Clinical Characteristics
A total of 175 patients (102 men and 73 women) were included in this study. The average age was 44.75 ± 13.65 years old. A total of 132 patients (75.4%, all in moderate type) were classified into the non-severe group, and 43 patients (24.6%, 41 in severe type and 2 in critical type) were classified into the severe group. There were no patients with mild type recruited in this study. Patients in the severe group were older than those in the non-severe group (50.63 ± 13.29 vs. 42.89 ± 13.27 years old, respectively, $p = 0.001$) and were hospitalized for 23.5 (20–30) days, longer than the hospitalization duration of non-severe patients [18 (15–23) days, $p < 0.001$]. Severe patients were more likely to have severe symptoms at onset. Chest tightness was reported in 25.6% of the severe group and 9.9% of the non-severe group. Underlying comorbidities, especially cardiovascular and endocrinal diseases were more frequently found in the severe patients. Lower lymphocyte cell counts, lower lactate dehydrogenase (LDH), and
higher aminotransferase (AST) levels were seen in severe cases (Tables 1, 2).

**Radiological Findings During Hospitalization**
A total of 714 scans from 175 patients were evaluated including 509 scans from the non-severe group and 205 from the severe group. Detailed information on the first scan, last scan, and all scans are summarized in Supplementary Tables 2, 3, and Table 2, respectively. Patients underwent their first CT scan on day 7 (range: 5–10) of the course on average with no difference between the non-severe and severe groups.

During the period of hospitalization, patients in the severe group had a higher Extent Score than those in the non-severe group (11.16 ± 6.20 vs. 5.19 ± 3.54, \( p < 0.001 \), Table 2). The occurrence percentages of radiological signs, such as reticular patterns (\( p < 0.001 \)), bronchiolectasis (\( p < 0.001 \)), air bronchogram (\( p < 0.001 \)), vascular enlargement (\( p < 0.001 \)), pleural thickening (\( p < 0.001 \)), pleural traction (\( p < 0.001 \)), pleural effusion (\( p < 0.001 \)), and mediastinal lymphadenopathy (\( p = 0.002 \)), were significantly higher in the scans of severe group patients than in those of non-severe group patients. The crazy-paving sign was more commonly seen in the non-severe patients (\( p = 0.014 \)).
### TABLE 1 | Predominant clinical characteristics and laboratory findings in patients from non-severe and severe group.

| Characteristics | All patients (n = 175) | Non-severe group (n = 132) | Severe group (n = 43) | p-value |
|-----------------|------------------------|---------------------------|----------------------|---------|
| Age             | 44.79 ± 13.65          | 42.89 ± 13.27            | 50.63 ± 13.29        | 0.001   |
| Gender, male/female | 102/73               | 73/59                    | 29/14                | 0.221   |
| Course          |                        |                           |                      |         |
| Admission duration**, median (1/4–3/4 quantile), day | 19 (16–26)               | 18.00 (15–23)          | 23.50 (20–30) | <0.001  |
| ICU duration, median (1/4–3/4 quantile), day | 9.50 (6–15)               | /                        | 9.50 (6–15)        | /       |
| Course***, median (1/4–3/4 quantile), day | 25 (20–31)               | 24 (19–29)               | 31 (27–35)          | <0.001  |
| Symptom         |                        |                           |                      |         |
| Fever           | 148 (84.6%)            | 111 (84.1%)               | 37 (86.1%)           | 0.948   |
| Cough           | 94 (53.7%)             | 68 (51.5%)                | 26 (60.5%)           | 0.340   |
| Chest tightness | 24 (13.7%)             | 13 (9.8%)                 | 11 (25.6%)           | 0.019   |
| Fatigue         | 25 (14.3%)             | 17 (12.9%)                | 8 (18.6%)            | 0.496   |
| Diarrhea        | 5 (2.9%)               | 5 (3.8%)                  | 0 (0%)               | 0.336*  |
| Headache        | 5 (2.9%)               | 5 (3.8%)                  | 0 (0%)               | 0.336*  |
| Others          | 1 (2.0%)               | 1 (0.8%)                  | 0 (0%)               | 1.000*  |
| Underlying comorbidity |            |                           |                      |         |
| Yes/no          | 48/127                 | 30/102                    | 18/25                | 0.025   |
| Endocrine system disease | 23 (13.1%)         | 13 (9.9%)                 | 10 (23.3%)           | 0.045   |
| Digestive system disease | 10 (5.7%)       | 8 (6.1%)                  | 2 (4.7%)             | 1.000   |
| Cardiovascular and cerebrovascular disease | 11 (6.3%)       | 5 (3.8%)                  | 6 (14.0%)            | 0.028*  |
| Malignancy      | 3 (1.7%)               | 1 (0.8%)                  | 2 (4.7%)             | 0.150*  |
| Mental disease  | 2 (1.1%)               | 1 (0.8%)                  | 1 (2.3%)             | 0.432*  |
| Respiratory system disease | 2 (1.1%)         | 1 (0.8%)                  | 1 (2.3%)             | 0.432*  |
| Other           | 5 (2.9%)               | 4 (3.0%)                  | 1 (2.3%)             | 1.000*  |
| Laboratory test |                        |                           |                      |         |
| White blood cell count, mean ± sd, × 10^9/L | 5.53 ± 2.33               | 5.32 ± 1.96              | 6.35 ± 3.29         | 0.274   |
| Lymphocyte count, mean ± sd, × 10^9/L | 1.09 ± 0.44               | 1.19 ± 0.43              | 0.80 ± 0.35         | <0.001  |
| Lactate dehydrogenase, mean ± sd, U/L | 260.43 ± 95.46             | 242.80 ± 65.69           | 341.39 ± 154.50     | <0.001* |
| C-reactive protein, mean ± sd, mg/L | 28.37 ± 35.67             | 21.18 ± 26.76            | 50.28 ± 48.70       | <0.001* |
| Procalcitonin, median (range), ng/mL | 0.09 ± 0.38               | 0.10 ± 0.42              | 0.06 ± 0.05         | 0.339*  |
| Alanine aminotransferase, mean ± sd, U/L | 39.50 ± 44.99             | 38.60 ± 47.59            | 42.55 ± 35.20       | 0.078*  |
| Aspartate aminotransferase, mean ± sd, U/L | 32.76 ± 30.07             | 31.99 ± 32.95            | 35.30 ± 17.52       | 0.008*  |
| Therapeutic strategy |            |                           |                      |         |
| Antiviral therapy | 169 (96.6%)            | 127 (96.2%)               | 42 (97.7%)           | 1.000*  |
| Oxygen inhalation | 121 (69.1%)            | 78 (59.1%)                | 43 (100.0%)          | <0.001* |
| Antibiotic treatment | 81 (46.3%)            | 51 (38.6%)                | 30 (69.8%)           | <0.001  |
| Interferon therapy | 44 (25.1%)             | 37 (28.0%)                | 7 (16.3%)            | 0.182   |
| Glucocorticoid therapy | 7 (4.0%)              | 4 (3.0%)                  | 3 (7.0%)             | 0.001   |

*Wilcoxon’s rank-sum test and Fisher’s exact test were used if non-normal distribution or heterogenous variance of the data was detected.
**Admission duration was calculated from the 1st day of hospitalization to the day of discharge.
***Course was calculated from the day of onset to the day of discharge.

The p value in bold indicates that P is less than 0.05 and is statistically significant.

The opacity was changed as the disease progressed. Overall, the evolution of the infiltrates from all the patients was observed from GGO to mixed consolidation and then from mixed consolidation to GGO at discharge (Figure 2). The normal CT findings before discharge were only observed in eight non-severe patients, accounting for 4.6% (8/175) of all participants.

### Radiological Findings at the Convalescence Stage

Among 175 participants, 135 (112 non-severe and 23 patients with severe COVID-19) underwent follow-up CT scans after discharge. Eight non-severe patients with complete pulmonary absorption at discharge and 32 patients (12 non-severe and 20 severe patients) who were lost to follow-ups were excluded. A
| Imaging manifestation | All scans (714 scans from 175 patients) | Non-severe group scans (509 scans from 135 patients) | Severe group scans (205 scans from 43 patients) | p-value |
|-----------------------|----------------------------------------|-------------------------------------------------|-----------------------------------------------|---------|
| Number of Scans per case | 4.07 ± 1.54 | 3.86 ± 1.45 | 4.72 ± 1.67 | 0.004 |
| **Period** | | | | |
| Between Onset and the CT Scan, median (1/4–3/4 quartile), day | 14 (9–20) | 14 (8–19) | 16 (10–23) | 0.003* |
| Between Onset and the 1st CT Scan, median (1/4–3/4 quartile), day** | 7 (5–10) | 7 (4–10) | 7 (4–11.5) | 0.581 |
| Between Onset and the last CT Scan, median (1/4–3/4 quartile), day** | 22 (16.5–26) | 20 (16–25) | 25 (20.5–29) | 0.004 |
| **Involved lobes** | | | | |
| Right upper lobe | 535 (74.9%) | 339 (66.6%) | 196 (95.6%) | <0.001 |
| Right middle lobe | 427 (59.8%) | 266 (52.3%) | 161 (78.5%) | <0.001 |
| Right lower lobe | 608 (85.2%) | 412 (80.9%) | 196 (95.6%) | <0.001 |
| Left upper lobe | 511 (71.6%) | 326 (64.1%) | 185 (90.2%) | <0.001 |
| Left lower lobe | 632 (88.5%) | 431 (84.7%) | 201 (98.1%) | <0.001 |
| **Location of Lesions** | | | | |
| Subpleural | 410 (57.4%) | 325 (63.9%) | 85 (41.5%) | <0.001* |
| Central | 7 (1.0%) | 5 (1.0%) | 2 (1.0%) | |
| Both | 282 (39.5%) | 165 (32.4%) | 117 (57.1%) | |
| None | 15 (2.1%) | 14 (2.8%) | 1 (0.5%) | |
| **Extent of lesions** | | | | |
| Unifocal | 37 (5.2%) | 36 (7.1%) | 1 (0.5%) | <0.001* |
| Multi-focal | 443 (62.0%) | 367 (72.1%) | 76 (37.1%) | <0.001 |
| Diffuse | 219 (60.7%) | 92 (18.1%) | 127 (62.0%) | |
| None | 15 (2.1%) | 14 (2.8%) | 1 (0.5%) | |
| Extent Score | 7.19 ± 5.13 | 5.19 ± 3.54 | 11.16 ± 6.20 | <0.001* |
| **The existence of opacification** | | | | |
| GGO | 139 (19.5%) | 119 (23.4%) | 20 (9.8%) | <0.001* |
| Mixed (mainly GGO) | 297 (41.6%) | 208 (40.9%) | 89 (43.4%) | |
| Mixed (mainly consolidation) | 241 (33.8%) | 154 (30.3%) | 87 (42.5%) | |
| Consolidation | 22 (3.1%) | 14 (2.8%) | 8 (3.9%) | |
| None | 15 (2.1%) | 14 (2.8%) | 1 (0.5%) | |
| Shape of lesions | | | | |
| Nodular | 6 (0.9%) | 5 (1.0%) | 1 (0.5%) | <0.001* |
| Linear | 21 (2.9%) | 20 (3.9%) | 1 (0.5%) | |
| Patchy | 467 (65.4%) | 399 (78.4%) | 68 (33.2%) | |
| Large patchy | 205 (28.7%) | 71 (14.0%) | 134 (65.4%) | |
| None | 15 (2.1%) | 14 (2.8%) | 1 (0.5%) | |
| Halo sign | 115 (16.1%) | 83 (16.3%) | 28 (13.7%) | 0.442* |
| Existence Period, day | 11 (7–16.5) | 11 (8–15) | 10 (5–19.25) | 0.663 |
| **Reverse Halo Sign** | | | | |
| Existence Period, day | 16 (2.2%) | 11 (2.2%) | 5 (2.4%) | 0.785* |
| Reticular patterns | 231 (32.4%) | 108 (15.1%) | 123 (60.0%) | <0.001 |
| Existence Period, day | 14 (9–20) | 11 (8–15) | 17 (12–23.5) | <0.001 |
| Air Bronchogram | 268 (37.5%) | 155 (30.5%) | 112 (55.1%) | <0.001 |
| Existence Period, day | 12 (8–18) | 10 (7–15) | 16 (11–22) | 0.006 |
| Bronchiectasis | 74 (10.4%) | 24 (4.7%) | 50 (24.4%) | <0.001 |
| Existence Period, day | 16.5 (11.25–23) | 11 (6.75–11.25) | 18 (14–25.75) | 0.188 |
| Vascular enlargement | 284 (39.8%) | 166 (32.6%) | 118 (57.6%) | <0.001 |

(Continued)
TABLE 2 | Continued

| Imaging manifestation | All scans (714 scans from 175 patients) | Non-severe group scans (509 scans from 135 patients) | Severe group scans (205 scans from 43 patients) | p-value |
|-----------------------|----------------------------------------|-----------------------------------------------------|-------------------------------------------------|---------|
| Existence Period, day | 12 (8–18)                              | 11 (7–16)                                           | 15 (10–22.75)                                   | <0.001* |
| Crazy-paving sign     | 113 (15.8%)                            | 95 (18.7%)                                          | 18 (8.8%)                                       | 0.014   |
| Pleural thickening    | 408 (57.1%)                            | 242 (47.5%)                                         | 166 (81.0%)                                     | <0.001  |
| Pleural traction      | 325 (45.5%)                            | 184 (36.2%)                                         | 141 (68.8%)                                     | <0.001  |
| Pleural effusion      | 40 (6.0%)                              | 17 (3.3%)                                           | 23 (11.2%)                                      | <0.001  |
| Mediastinal Lymphadenopathy | 34 (4.8%)                 | 17 (3.3%)                                           | 19 (9.3%)                                       | 0.002   |
| Change of liver density | 8.41 ± 9.33                           | 9.23 ± 8.19                                         | 7.05 ± 10.86                                    | 0.124   |

*Wilcoxon’s rank-sum test and Fisher’s exact test were used when non-normal distribution or heterogeneous variance of the data.

The periods were calculated from the first CT scan in 175 patients.

Existence period: The existence period of certain positive radiological findings.

The p value in bold indicates that P is less than 0.05 and is statistically significant.

FIGURE 2 | The changes in the Extent Score and opacification in the patients with COVID-19 during hospitalization and follow-ups. The opacities of lesions in the convalescent stage were mainly GGOs with a relatively high Extent Score.

Total of 299 follow-up scans from 135 patients were studied. Lesions in 68 (50.4%) patients were completely absorbed with a median absorption period of 42.50 (IQR: 34.75–55.25) days. Patients with older age (46.81 ± 13.66 years old) and severe clinical type were more likely to have abnormal CT findings in the follow-up scans (Table 3). By the end of our observation, 67 patients still presented with pulmonary abnormalities. Among them, parenchymal bands were observed in 23 patients whereas opacifications were observed in the other 44 patients (Table 4).

The parenchymal bands were usually distributed in the subpleural regions and GGO was the main manifestation of opacification. After comparison, patients with incomplete lesion absorption were
TABLE 3 | The comparison of clinical and CT manifestations during hospitalization between the patients with coronavirus disease 2019 (COVID-19) with normal and abnormal CT findings in the last follow-up scan after discharge.

| Periods                          | All patients (n = 135) | Normal (n = 68) | Abnormal (n = 67) | p-value |
|---------------------------------|------------------------|-----------------|-------------------|---------|
| Pulmonary Lesion Absorption Period, median (IQR), day | /                      | 42.50 (34.75–55.25) | /                 | /       |
| Period between discharge and the last follow-up CT scan, median (IQR), day | 29.00 (28.00–54.50)    | 28.00 (27.75–32.25) | 33.00 (28.00–62.50) | 0.019*  |
| Period between onset and the last follow-up CT scan, median (IQR), day | 57.00 (47.50–76.50)    | 53.00 (47.00–65.25) | 60.00 (48.50–87.00) | 0.041*  |
| **Clinical information**        |                        |                 |                   |         |
| Age                             | 44.15 ± 13.67          | 41.53 ± 13.26   | 46.81 ± 13.66     | 0.024   |
| Gender, male/female             | 79/56                  | 42/26           | 37/30             | 0.487   |
| Underlying comorbidity yes/no   | 41/94                  | 21/47           | 20/47             | 1.000   |
| Clinical group: non-severe/severe| 112/23                 | 63/5            | 49/18             | 0.003   |
| **CT manifestations from the scan at the peak stage†** |                        |                 |                   |         |
| Morphology†                     |                        |                 |                   | <0.001  |
| Nodular                         | 1 (0.7%)               | 1 (1.5%)        | 0 (0%)            |         |
| Large-path                      | 42 (31.1%)             | 12 (17.6%)      | 30 (44.8%)        |         |
| Linear                          | 8 (5.9%)               | 8 (11.8%)       | 0 (0%)            |         |
| Patchy                          | 84 (62.2%)             | 47 (69.1%)      | 37 (55.2%)        |         |
| Extent†                         | 7.34 ± 4.69            | 6.01 ± 3.73     | 8.69 ± 5.18       | 0.001   |
| **CT manifestations from the scan before discharge*** |                        |                 |                   | 0.001   |
| Lesion involvement*             |                        |                 |                   |         |
| None                            | 7 (5.2%)               | 6 (8.8%)        | 1 (1.5%)          |         |
| Diffuse                         | 23 (17%)               | 5 (7.4%)        | 18 (26.9%)        |         |
| Multifocal                      | 92 (68.1%)             | 47 (69.1%)      | 45 (67.2%)        |         |
| Unifocal                        | 13 (9.6%)              | 10 (14.7%)      | 2 (4.5%)          |         |
| RUL*                           | 86 (63.7%)             | 34 (50%)        | 52 (77.6%)        | 0.001   |
| RML*                           | 62 (45.9%)             | 21 (30.9%)      | 41 (61.2%)        | <0.001  |
| **Distribution**                |                        |                 |                   | 0.001   |
| None                            | 6 (4.4%)               | 5 (7.4%)        | 1 (1.5%)          |         |
| Both                            | 41 (30.4%)             | 12 (17.6%)      | 29 (43.3%)        |         |
| Subpleural                      | 88 (65.2%)             | 51 (75%)        | 37 (55.2%)        |         |
| **Morphology**                  |                        |                 |                   | 0.002   |
| None                            | 7 (5.2%)               | 6 (8.8%)        | 1 (1.5%)          |         |
| Nodular                         | 1 (0.7%)               | 1 (1.5%)        | 0 (0%)            |         |
| Large-patchy                    | 18 (13.3%)             | 3 (4.4%)        | 15 (22.4%)        |         |
| Linear                          | 3 (2.2%)               | 3 (4.4%)        | 0 (0%)            |         |
| Patchy                          | 106 (78.5%)            | 55 (80.9%)      | 51 (76.1%)        |         |
| Reticulation*                   | 19 (14.1%)             | 2 (2.9%)        | 17 (25.4%)        | 0.005   |
| Extent*                         | 5.19 ± 4.17            | 3.68 ± 2.46     | 6.72 ± 4.95       | <0.001  |

Pulmonary lesion absorption period: The period from onset to the first CT scan with normal appearance.
In the comparison of CT findings between the two groups, only the imaging manifestations with significant difference were displayed in the table.
†CT manifestations from the scan at the peak stage.
*CT manifestations from the scan before discharge.
The p value in bold indicates that P is less than 0.05 and is statistically significant.

detected to have diffuse lesions with a higher Extent Score both at the peak stage and before discharge (Table 3).

It was notable that the parenchymal bands in the nine patients (9/23, 39.1%) disappeared in the last follow-up scan. The typical cases are demonstrated in Figure 3. We have compared the clinical, CT manifestations among the 23 patients with residual parenchymal bands and those nine patients mentioned above. Patients with unabsorbed fibrosis-like lesions had a higher percentage of lesion involvement in the right
upper lobe with a patchy/large-patchy appearance at discharge (Table 5).

In the univariate Cox regression analyses, one clinical, two laboratories, and five CT features from the last scan before discharge were significantly associated with incomplete absorption of pulmonary lesions (all \( p < 0.05 \)). The Cox proportional hazards model retained age [hazard ratio (HR), 0.95; 95% CI, 0.95–0.99; \( p = 0.003 \)], LDH (HR, 0.99; 95% CI, 0.99–1.00; \( p = 0.026 \)), procalcitonin (HR, 8.72; 95% CI, 1.04–73.03; \( p = 0.046 \)), diffuse distribution (HR, 0.28; 95% CI, 0.09–0.92; \( p = 0.013 \)), subpleural abnormalities (HR, 2.15; 95% CI, 1.17–3.92; \( p = 0.013 \)), linear lesions (HR, 4.58; 95% CI, 1.22–17.11; \( p = 0.002 \)), nodular lesions (HR, 33.07; 95% CI, 3.58–305.74; \( p = 0.002 \)), and the existence of pleural traction (HR, 0.41; 95% CI, 0.22–0.78; \( p = 0.006 \)) as independent predictive factors (Table 6). The best cut-off value of this Cox model was \(-0.85\) with a C-index of 0.747 ± 0.033 that could stratify patients with complete and incomplete pulmonary absorption successfully (\( p < 0.001 \), log-rank test). By Kaplan–Meier analysis, the probability of patients of the low-risk group to have pulmonary lesions fully absorbed within 90 days reached 91.7%, whereas the probability in the high-risk group was only 22.7% (Figure 4).

**DISCUSSION**

After the worldwide outbreak of SARS, MERS, and COVID-19, coronaviruses have attracted great attention in the global healthcare system (20–24). Chest CT scans have been widely used as screening methods to identify patients with COVID-19 pneumonia. Despite the debate around the diagnostic importance of CT and NAAT, a chest CT is currently no longer recommended as the first choice of COVID-19 diagnosis due to the radiation risk. However, it is valuable to study the dynamic changes of COVID-19 on the multiple chest CT scans, which
could help us optimize the management and follow-up plans of the disease (7, 25).

A total of 714 serial scans from 175 patients during hospitalization and 299 follow-up scans from 135 patients obtained in our cohort provided us with an opportunity to study the longitudinal pulmonary changes in COVID-19. To the best of our knowledge, although many studies have been conducted to describe the longitudinal pulmonary changes in the patients with COVID-19 in the acute period, few have investigated the absorption of lesions at the convalescent stage. Lesions of COVID-19 induced pneumonia were distributed mainly in the subpleural region and progressed from patches to large patches with hardly noticeable pleural changes. With the progression of the disease, density changes were seen with a regular pattern of GGO-consolidation-GGO, which was aligned with previous reports (26–28). The pathological findings revealed that edema, proteinaceous exudate, and hyperplasia of pneumocytes with patchy inflammatory cellular infiltration and the absence of hyaline membranes were histological changes in the early stage of COVID-19 which presented as GGOs at the onset (26, 29). Diffuse alveolar damage with cellular fibro-myxoid exudates corresponded to the acute respiratory distress syndrome (ARDS), presented with a consolidation-predominant appearance on the CT images (5). In the convalescent period, GGOs might also represent the existence of proteinaceous or fibro-myxoid exudates that would be absorbed gradually. Since it is difficult to distinguish the GGO lesions in different stages, it is recommended to take the time course into consideration when making diagnoses and differential diagnoses, rather than merely basing them on the CT findings. With the progression of density, the areas of involved pulmonary tissues, which was reflected by the Extent Score, decreased significantly as well (at peak vs. at discharge: 7.34 ± 4.69 vs. 5.19 ± 4.17, \( p < 0.001 \)). Several studies have addressed the importance of the Extent Score in the evaluation of the severity of patients with COVID-19 (17, 30, 31). Moreover, according to this study results, the
TABLE 5 | The comparison of clinical manifestations between the patients with COVID-19 with absorbed parenchymal bands and residual parenchymal bands in the last follow-up scan after discharge.

| Patients with absorbed parenchymal bands (n = 9) | Patients with residual parenchymal bands (n = 23) | p-value |
|------------------------------------------------|-------------------------------------------|---------|
| **Periods** | | | |
| Pulmonary Lesion Absorption Period, median (IQR), day | 40.00 (30.25–41.50) | / | / |
| Period between discharge and the latest follow-up CT scan, median (IQR), day | 28.00 (27.00–29.00) | 55.00 (29.00–138.50) | 0.034* |
| Period between onset and the latest follow-up CT scan, median (IQR), day | 40.00 (30.25–41.50) | 75.00 (55.00–168.00) | 0.068* |
| **Clinical information** | | | |
| Age | 45.39 ± 14.16 | 40.11 ± 14.04 | 0.304 |
| Gender, male/female | 42/26 | 37/30 | 0.132 |
| Underlying comorbidity yes/no | 21/47 | 20/47 | 0.604 |
| Clinical group: non-severe/severe | 63/5 | 49/18 | 1.000 |
| **Morphology†** | | | |
| Nodular | 0 (0%) | 0 (0%) | <0.002 |
| Large-patchy | 3 (33.3%) | 12 (52.2%) | |
| Linear | 4 (44.4%) | 0 (0%) | |
| Patchy | 2 (22.2%) | 11 (47.8%) | |
| RUL† | 2 (22.2%) | 18 (78.3%) | 0.005 |
| **Morphology*** | | | |
| None | 2 (22.2%) | 1 (4.3%) | 0.004 |
| Nodular | 0 (0%) | 0 (0%) | |
| Large-patchy | 1 (11.1%) | 3 (13%) | |
| Linear | 3 (33.3%) | 0 (0%) | |
| Patchy | 3 (33.3%) | 19 (83.6%) | |

The p value in bold indicates that P is less than 0.05 and is statistically significant. † CT manifestations from the scan at the peak stage. * CT manifestations from the scan before discharge.

TABLE 6 | Results of univariate and multivariate Cox proportional hazard regression analyses.

| Variable | Univariate Cox hazard analysis | Multivariate Cox hazard analysis |
|----------|--------------------------------|----------------------------------|
|          | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Clinical Information (3) | | | | |
| Age | 0.97 (0.95–0.99) | <0.001 | 0.95 (0.95–0.99) | 0.003 |
| LDH | 0.99 (0.99–1) | <0.001 | 0.99 (0.99–1.00) | 0.026 |
| Procalcitoninb | 1.9 (1.1–3.1) | 0.015 | 8.72 (1.04–73.03) | 0.046 |
| CT manifestations before dischargea (5) | | | | |
| Lesion involvement-diffusea,b | 0.22 (0.087–0.55) | <0.001 | 0.28 (0.09–0.92) | 0.036 |
| Distribution-subpleurala,b | 1.8 (1.1–3.2) | 0.030 | 2.15 (1.17–3.92) | 0.013 |
| Morphology-linar,b | 9.0 (2.7–30) | <0.001 | 4.58 (1.22–17.11) | 0.024 |
| Morphology-Nodulara,b | 31 (3.6–270) | 0.002 | 33.07 (3.58–305.74) | 0.002 |
| Pleural tractiona | 0.4 (0.23–0.7) | 0.001 | 0.41 (0.22–0.78) | 0.006 |

a The CT findings were analyzed based on the last chest CT scan before discharge. 
b The “total absorption” was set as the endpoint of the Cox Regression model, therefore, features with HR value over 1.0 were regarded as the protective factors.

opacities changed before shrinkage of the affected areas could be observed. Therefore, to evaluate the severity of the disease, we thought attention should be given to the opacification pattern of lesions as well.

Based on our findings, several radiological features possibly indicated the severity of the disease at the acute stage. It is worth mentioning that the CT sign of vascular enlargement was frequently seen in severe patients during hospitalization (57.6%), but was rarely seen in non-severe ones or patients after discharge. It was reported that in patients with COVID-19, due to inflammation and the activation of arteriovenous anastomoses, venous blood flow increases and results in the
vascular dilatation in the venous compartment (32, 33). This could help to understand the sign of vascular enlargement in severe patients with COVID-19 (34). Since the plain CT scans in this study limited the accurate recognition of blood vessels, we suggest that further studies with enhanced chest CT data be conducted to explore the reason for vascular enlargement in patients with COVID-19.

According to the guidelines provided by the Government of China, all COVID-19 patients should undergo at least two follow-up chest CT scans at 2 weeks and 1 month, respectively, after discharge. For those patients with unabsorbed lesions detected after discharge, it was recommended to take the CT scans several months later until complete absorption was observed. However, recommendations were raised based on our experiences with SARS. In this study, the follow-up period of our 135 patients ranged from 8 to 174 days after discharge. In SARS-related studies, 17 patients were followed up, consolidation generally resolved completely (n = 4) or to minimal residual opacities; six (55%) of 11 patients with ground-glass opacities had substantial residual disease (CT scores >5) on final scans (35). Compared with the residual pulmonary consequences in SARS patients, the percentage and extensiveness of these pulmonary abnormalities were increasingly lower (36, 37). In the current study, 68 patients had their lesions totally absorbed, with a median

![Pulmonary Lesion Absorption Curve](image)

**FIGURE 4** A Kaplan–Meier curve is depicted to demonstrate the ability of Cox regression to discriminate complete and incomplete pulmonary absorption in patients. Cumulative number of events: cumulative number of patients who had pulmonary lesions completely absorbed. The number of censorings: the number of patients who had pulmonary lesions completely absorbed or lost follow-ups before the end of our observation.
duration of 42.50 days since onset. Among the 67 patients with unabsorbed abnormalities, approximately one-third presented with parenchymal bands, while opacities were observed in the other 40 patients with GGOs as the predominant presentation (38, 39). The patients with residual opacities were mostly male with a shorter follow-up duration which indicated that the parenchymal band might be the next stage after GGO absorption.

The parenchymal band is widely accepted as a consequence of linear atelectasis distal to the narrowed bronchus, or pleuro-parenchymal fibrosis, which could potentially affect the pulmonary function. This fibrosis-like abnormality was reported by Yu et al. and Gregory Antonio et al. as one of the consequences of coronavirus infection with a limited follow-up duration (14, 40). In this study, the parenchymal bands were absorbed in nine patients (9/68, 13.2%) with a median absorption period of 40 days since the onset (range: 26–174 days). After comparison between patients with absorbed and unabsorbed parenchymal bands, only the location of the pulmonary lesions (especially in the right upper lobe) demonstrated a difference. Based on these findings, we assumed that the absorbed parenchymal bands may only represent temporary atelectasis and that most of them would be absorbed gradually. As the absorption duration of the parenchymal bands varies significantly, it is recommended for patients with fibrosis-like residuals to have long-term follow-ups.

At the beginning of the outbreak, according to guidelines from the government of China, patients with COVID-19 in this study were not required to undergo a pulmonary function test. A few studies have mentioned that the average pulmonary function was normal in patients after mild/moderate COVID-19. The patients after severe/critical COVID-19 generally had lower lung volumes that were still within the normal range (41, 42).

Since nearly half of the patients presented with residual pulmonary lesions in their last follow-up scan, it was important to determine which factors could actually affect the absorption status of the COVID-19 related pulmonary lesions. A set of eight clinical and CT features were selected as risk factors. Among them, high procalcitonin level, subpleural distribution of lesions, and lesions with linear and nodular shape in CT images before discharge worked as protective factors since these features indicated limited lesion involvement at the time of discharge, which might be due to an adaptive, beneficial, and therapeutic response to the pathogens. Procalcitonin has been widely used in identifying infectious diseases in recent years and is now recognized as a validated serological marker for the identification of microbial infections. This is of great significance in the diagnosis of early infection and the assessment of the extent of early infection (43). We assumed that the early detection of a high level of procalcitonin might help the patients that receive early intervention treatment, thus resulting in the faster absorption of the lesions. The peripheral subpleural pulmonary lobules are well-developed with rich blood flow and lymph system, facilitating the absorption of infiltrates, which could explain why subpleural distribution of lesions worked as a protective factor. A high level of LDH, older age, the existence of diffuse lesion distribution, and pleural traction served as risk factors to delay absorption that was consistent with the previous studies. Among them, LDH, as one of the most important enzymes for anaerobic glycolysis and gluconeogenesis, was frequently elevated in severe patients, and pleural traction, a sign of pleural adhesion and hypertrophy caused by fibrin deposition, is also a sign of severe and long-term inflammation (44, 45). The current study results suggest that those patients were more likely to have residual lesions in the lungs. We could consider that in a young patient with low LDH and procalcitonin levels and subpleural linear/nodular pulmonary lesions before discharge, it may not be necessary to perform follow-up CT scans.

Based on these predictive factors, our Cox model could efficiently stratify patients into two groups: almost all patients in the low-risk group had their lesions absorbed in 3 months, while 50% of the patients in the high-risk group had pulmonary residuals even after 6 months. To monitor the absorption status and minimize radiation damage, we suggest that 3 months since onset could be an optimal timepoint to monitor the absorption status in discharged patients with COVID-19 rather than a 1-month CT follow-up.

As far as we know, this is the first study to report detailed time-course-based radiological findings from onset to 1-year follow-up. There are still several limitations in this study. First, we did not collect the dynamic changes in laboratory tests and lacked pulmonary function results. Second, the treatment might vary from February until now, which might bring changes to the radiological course of COVID-19. Third, we only enrolled the adult patients for this study; therefore, our results could not be generalized to children or pregnant women.

In conclusion, we found that the development of COVID-19 lesions evolved from GGO to consolidation and then from consolidation to GGO. The CT manifestations from scans at the peak stage and before discharge could help to predict the absorption status of pulmonary lesions. The parenchymal bands were observed to be absorbed in some COVID-19 cases and thus should not be regarded as irreversible fibrosis. Our Cox regression analysis indicated that 3 months since onset could be an optimal timepoint for radiological follow-up in the discharged patients.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because approval from the relevant authorities is required. Requests to access the datasets should be directed to susan_lyp@163.com.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Huashan Hospital Affiliated to Fudan University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
AUTHOR CONTRIBUTIONS
YL, LL, and BY conceived and designed this study. XL, YZhe, AX, XQ, and XY conducted the study and collected important background data. YZha, DW, and NM drafted the manuscript. All authors read and approved the final manuscript.

FUNDING
This project was supported by the Clinical Research Plan of SHDC (Grant No. SHDC2020CR4069), the Youth Program of National Natural Science Foundation of China (Fund No. 81901697), the Shanghai Sailing Program (Grant No. 21YF1404800), the Shanghai Municipal Science and Technology Major Project (No. 2018SHZDZX01), and the ZJ Lab. All the funding sources played no roles in the study.

ACKNOWLEDGMENTS
We would like to thank all the medical staff who assisted in the care of patients with COVID-19.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.711435/full#supplementary-material

REFERENCES
1. World Health Organization. (2020). Clinical Management of COVID-19: Interim Guidance, World Health Organization. Available online at: https://apps.who.int/iris/handle/10665/332302 (accessed May 27, 2020).
2. Worldometers. Coronavirus Cases. (2021). Available online at: https://www.worldometers.info/coronavirus/ (accessed April 20, 2021).
3. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. (2020) 579:265–9. doi: 10.1038/s41586-020-02088-3
4. Chan JF, Yuen KY, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with a novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. (2020) 395:514–23. doi: 10.1016/S0140-6736(20)30154-9
5. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. J Am Med Assoc. (2020) 324:782–93. doi: 10.1001/jama.2020.12839
6. Zhao YM, Wang Y, Li X, Li Q, Liu T, Li Y, et al. Incidentally discovered COVID-19 pneumonia: the role of diagnostic imaging. Eur Respir. (2020) 50:2101–13. doi: 10.1007/s00130-020-02671-6
7. Yu Y, Wang S, Tian T, Liu Y, Wang X, Guo F, et al. Development and validation of a prognostic nomogram based on clinical and CT features for adverse outcome prediction in patients with COVID-19. Korean J Radiol. (2020) 21:1007–17. doi: 10.3348/kjr.2020.0485
8. Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea. Korean J Radiol. (2020) 21:494–500. doi: 10.3348/kjr.2020.0132
9. Hanseil DM, Bankier AA, MacMahon H, McCloud TC, Müllner NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. (2008) 246:979–722. doi: 10.1148/radiol.2462070712
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. (2020) 25:100463. doi: 10.1016/j.eclinm.2020.100463
11. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1,014 cases. Radiology. (2020) 296:E32–40. doi: 10.1148/radiol.2020200110
12. Pozzessere C, Rotzinger DC, Ghaye B, Lamoth F, Beigelman-Aubry C. Radiology. (2020) 246:697–722. doi: 10.1148/radiol.2462070712
13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30181-1
14. Han Y, Wang J, Li X, Ren L, Zhao J, Hu Y, et al. Chest CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea. Korean J Radiol. (2020) 21:494–500. doi: 10.3348/kjr.2020.0132
15. Hanseil DM, Bankier AA, MacMahon H, McCloud TC, Müllner NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. (2008) 246:979–722. doi: 10.1148/radiol.2462070712
16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhnah, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
17. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. (2020) 92:418–23. doi: 10.1002/jmv.26234
18. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhnah, China. J Med Virol. (2020) 92:441–7. doi: 10.1002/jmv.25689
19. Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC, et al. Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study. EClinicalMedicine. (2020) 25:100484. doi: 10.1016/j.eclinm.2020.100484
20. Inui S, Fujikawa A, Jitsu M, Watanabe S, Suzuki Y, et al. Lung ground-glass opacities in COVID-19 pneumonia: a clinicopathological study. J Med Virol. (2020) 92:441–7. doi: 10.1002/jmv.25689
21. Han Y, Cao Y, Jiang N, Chen Y, Alwalid O, Zhang X, et al. Novel coronavirus disease 2019 (COVID-19) pneumonia progression course in 17 discharged patients: comparison of clinical and thin-section computed
tomography features during recovery. Clin Infect Dis. (2020) 71:723–31. doi: 10.1093/cid/ciaa271
27. Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. (2021) 9:747–54. doi: 10.1016/S2213-2600(21)00174-0
28. Zhang S, Bai W, Yue J, Qin L, Zhang C, Xu S, et al. Eight months follow-up study on pulmonary function, lung radiographic, and related physiological characteristics in COVID-19 survivors. Sci Rep. (2021) 11:13854. doi: 10.1038/s41598-021-93191-y
29. Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT severity score: an imaging tool for assessing severe COVID-19. Radiol Cardiotoracic Imaging. (2020) 2:e200047. doi: 10.1148/ryct.2020200047
30. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. Clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol. (2020) 55:327–31. doi: 10.1097/RLI.0000000000000672
31. Lyu P, Liu X, Zhang R, Shi L, Gao J. The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics. Invest Radiol. (2020) 55:412–21. doi: 10.1097/RLI.0000000000000689
32. Qanadli SD, Rocha AC, Rotzinger DC. Case report: intrapulmonary arteriovenous anastomoses in COVID-19-related pulmonary vascular changes: a new player in the arena? Front Med. (2021) 8:639152. doi: 10.3389/fmed.2021.639152
33. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelitis, thrombosis, and angiogenesis in COVID-19. Eur Radiol. (2020) 38:719–39. doi: 10.1183/13993003.03690-2020
34. Li Q, Huang XT Li CH, Liu D, Lv FJ, CT. features of coronavirus disease 2019 (COVID-19) with an emphasis on the vascular enlargement pattern. Eur J Radiol. (2021) 134:109442. doi: 10.1016/j.ejrad.2020.109442
35. Ooi GC, Khong PL, Yiu WC, Zhou LJ, Ho JC, et al. Severe acute respiratory syndrome: temporal lung changes at thin-section CT in 30 patients. Radiology. (2003) 220:836–44. doi: 10.1148/radiol.2203030853
36. Koo HJ, Lim S, Choe J, Choi SH, Sung H, Do KH. Radiographic and CT features of viral pneumonia. Radiographics. (2018) 38:719–39. doi: 10.1148/radiographics.2018170048
37. Ooi CG, Khong PL, Ho JC, Lam B, Wong WM, Yiu WC, et al. Severe acute respiratory syndrome: radiographic evaluation and clinical outcome measures. Radiology. (2003) 229:500–6. doi: 10.1148/radiol.2292030737
38. Feinstein MB, DeSouza SA, Moreira AL, Stover DE, Heelan RT, Iyriboz TA, et al. A comparison of the pathological, clinical and radiographical, features of cryptoergic organising pneumonia, acute fibrinous and organising pneumonia and granulomatous organising pneumonia. J Clin Pathol. (2013) 68:441–7. doi: 10.1136/jclinpath-2014-202626
39. Mehrjardi MZ, Kakhossee S, Pourabdollah M. Radio-pathological correlation of organizing pneumonia (OP): a pictorial review. Br J Radiol. (2017) 90:1–7. doi: 10.1259/bjr.20160723
40. Antonio GE, Wong KT, Hui DS, Wu A, Lee N, Yuen EH, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. (2003) 228:810–5. doi: 10.1148/radiol.2283030726
41. Guler SA, Ebner L, Aubry-Beigelman C, Bridevaux PO, Brutsche M, Clarenbach C, et al. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. (2021) 57:2003690. doi: 10.1183/13993003.03690-2020
42. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. (2021) 397:220–32. doi: 10.1016/S0140-6736(20)32656-8
43. An PJ, Zhu YZ, Yang LP. Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications. Pharmaco Res. (2020) 159:104946. doi: 10.1016/j.phrs.2020.104946
44. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med. (2020) 38:1722–6. doi: 10.1016/j.ajem.2020.05.073
45. Zhang D, Zhang C, Li X, Zhao J, An C, Peng C, et al. Thin-section computed tomography findings and longitudinal variations of the residual pulmonary sequelae after discharge in patients with COVID-19: a short-term follow-up study. Eur Radiol. (2021) 31:7172–83. doi: 10.1007/s00330-021-07799-9

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhao, Wang, Mei, Yin, Li, Zheng, Xiao, Yu, Qiu, Lu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.